Press release
Primary Ciliary Dyskinesia Pipeline 2025: Groundbreaking Clinical Advancements by 4+ Global Leaders - DelveInsight | Featuring Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuti
Primary Ciliary Dyskinesia Pipeline 2025
As Primary Ciliary Dyskinesia (PCD) increasingly impacts populations worldwide and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the demand for safer and more effective treatments is growing. According to DelveInsight, the PCD pipeline includes over four pharmaceutical and biotech companies actively developing more than four therapeutic candidates. These therapies are at various stages of clinical and preclinical development, reflecting substantial innovation and dedication to tackling this significant public health challenge.
DelveInsight's "Primary Ciliary Dyskinesia Pipeline Insight 2025" report offers a comprehensive and strategic assessment of the current R&D landscape. It provides insights into clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key initiatives by leading companies such as Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, and ethris GmbH. The report serves as an essential resource for researchers, healthcare investors, and decision-makers seeking to understand the evolving PCD therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Primary Ciliary Dyskinesia Drug Development [https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Key Takeaways from the Primary Ciliary Dyskinesia Pipeline Report
*
DelveInsight's report on the Primary Ciliary Dyskinesia (PCD) pipeline highlights a dynamic landscape, with over four companies actively developing more than four therapeutic candidates for PCD treatment.
*
In June 2024, the FDA granted Orphan Drug Designation to RCT1100, an inhaled mRNA therapy from ReCode Therapeutics, specifically targeting PCD caused by DNAI1 gene mutations.
*
Leading companies in the PCD space-including Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, and ethris GmbH-are actively investigating new drugs to enhance the treatment landscape. Promising pipeline candidates, such as P 1037 and others, are progressing through various stages of development.
Primary Ciliary Dyskinesia Overview:
Primary ciliary dyskinesia (PCD) is a rare genetic disorder, usually inherited in an autosomal recessive pattern, in which the tiny hair-like structures called cilia-responsible for moving mucus through the respiratory tract-do not function properly. Impaired ciliary activity prevents efficient clearance of mucus from the lungs, sinuses, and middle ears, allowing bacteria and other irritants to accumulate and cause recurrent respiratory infections. Symptoms often appear shortly after birth and may include coughing, gagging, choking, and lung collapse (atelectasis) due to respiratory distress. Over time, individuals with PCD frequently develop chronic infections in the lungs, sinuses, and ears, along with persistent coughing, excessive mucus production, and hearing loss.
Definitive diagnosis is typically achieved through genetic testing or microscopic examination of tissue samples from the lungs or sinuses, which can reveal structural abnormalities in the cilia using electron microscopy. Management focuses on maintaining lung function through airway clearance therapies, including routine sinus and ear irrigation. Treatment also involves antibiotics to fight infections, bronchodilators to ease breathing, corticosteroids to reduce inflammation, and mucolytics to thin and clear mucus.
Download the Primary Ciliary Dyskinesia sample report to know in detail about the Primary Ciliary Dyskinesia treatment market [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Primary Ciliary Dyskinesia Pipeline Analysis
The Primary Ciliary Dyskinesia pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Primary Ciliary Dyskinesia Market.
*
Categorizes Primary Ciliary Dyskinesia therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Primary Ciliary Dyskinesia drugs under development based on:
*
Stage of development
*
Primary Ciliary Dyskinesia Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Primary Ciliary Dyskinesia Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Primary Ciliary Dyskinesia Licensing agreements
*
Funding and investment activities supporting future Primary Ciliary Dyskinesia market advancement.
Unlock key insights into emerging Primary Ciliary Dyskinesia therapies and market strategies here: https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Primary Ciliary Dyskinesia Emerging Drugs
*
P 1037: Parion Sciences
Parion Sciences is developing P-1037, a novel inhibitor of the epithelial sodium channel (ENaC) designed to treat respiratory diseases such as primary ciliary dyskinesia (PCD), cystic fibrosis, and chronic obstructive pulmonary disease (COPD), all characterized by thick, dehydrated airway mucus. By blocking sodium channels on airway surfaces, ENaC inhibitors like P-1037 help rehydrate mucus, restore mucociliary clearance, and improve lung function.
Primary Ciliary Dyskinesia Pipeline Therapeutic Assessment
Primary Ciliary Dyskinesia Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Primary Ciliary Dyskinesia By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Primary Ciliary Dyskinesia Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Primary Ciliary Dyskinesia Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Primary Ciliary Dyskinesia therapies and key Primary Ciliary Dyskinesia companies [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Primary Ciliary Dyskinesia Current Treatment Patterns
4. Primary Ciliary Dyskinesia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Ciliary Dyskinesia Late-Stage Products (Phase-III)
7. Primary Ciliary Dyskinesia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Ciliary Dyskinesia Discontinued Products
13. Primary Ciliary Dyskinesia Product Profiles
14. Primary Ciliary Dyskinesia Key Companies
15. Primary Ciliary Dyskinesia Key Products
16. Dormant and Discontinued Products
17. Primary Ciliary Dyskinesia Unmet Needs
18. Primary Ciliary Dyskinesia Future Perspectives
19. Primary Ciliary Dyskinesia Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Primary Ciliary Dyskinesia pipeline reports offerings [https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-ciliary-dyskinesia-pipeline-2025-groundbreaking-clinical-advancements-by-4-global-leaders-delveinsight-featuring-parion-sciences-recode-therapeutics-translate-bio-santhera-pharmaceuti]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Ciliary Dyskinesia Pipeline 2025: Groundbreaking Clinical Advancements by 4+ Global Leaders - DelveInsight | Featuring Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuti here
News-ID: 4227964 • Views: …
More Releases from ABNewswire
Giant Cell Arteritis Pipeline 2025: Key Clinical Developments by 80+ Global Inno …
DelveInsight's, "Giant-Cell Arteritis - Pipeline Insight, 2025," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Giant-Cell Arteritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Giant Cell Arteritis (GCA) becomes increasingly prevalent worldwide and…
Pheochromocytoma Pipeline 2025: Key Clinical Developments by Leading Global Inno …
DelveInsight's, "Pheochromocytoma - Pipeline Insight, 2025," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Pheochromocytoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Pheochromocytoma increasingly prevalent worldwide and contributing to comorbidities such as diabetes,…
Presbyopia Pipeline 2025: Innovative Clinical Developments by Leading Global Com …
DelveInsight's, "Presbyopia - Pipeline Insight, 2025" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As presbyopia becomes increasingly prevalent worldwide and is associated with comorbidities such…
Periodontal Disease market is projected to experience significant growth by 2032 …
Periodontal Disease market is projected to experience significant growth by 2032, driven by major players such as Dentsply Sirona Inc., Envista Holdings Corporation, A-dec Inc., J. Morita Corp., Straumann Group, BIOLASE, BEGO GmbH & Co. KG, Ultradent Products, and Yoshida Dental.
Key factors contributing to this growth include the rising prevalence of Periodontal Disease, increased investments in R&D, and the introduction of novel and emerging therapies during the forecast period 2019-2032.
Additionally,…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
